Current Report Filing (8-k)
July 17 2017 - 01:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported) July 17, 2017 (July 14, 2017)
MEDIFIRST SOLUTIONS, INC
(Exact name of registrant as specified
in its charter)
Nevada
|
|
000-55465
|
|
27-3888260
|
(State or other
|
|
(Commission File Number)
|
|
(IRS Employer
|
jurisdiction incorporation)
|
|
|
|
Identification No.)
|
|
|
|
|
|
4400 Route 9 South, Suite 1000, Freehold, NJ
|
|
07728
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including
area code: (732)-786-8044
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 Regulation
FD Disclosure
On July 14, 2017,
Medifirst Solutions, Inc. (the “Company”) issued a press release, in question and answer form, providing various updates
and information about the Company.
A copy of the press
release is attached herewith as Exhibit 99.1.
The information
in this Item 7.01 disclosure, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities under that Section. In addition, the information in this Item 7.01 disclosure, including Exhibits 99.1, shall not be
incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such filing.
2
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.
|
MEDIFIRST SOLUTIONS, INC.
|
|
|
Dated: July 17, 2017
|
By:
|
/s/ Bruce Schoengood
|
|
|
Bruce Schoengood
President and Chief Executive Officer
|